IP Library Granted Patent US 10,781,439
Granted Patent B2
US 10,781,439 · App. 15/473,672 · Granted Sep 22, 2020

Extraction of cfDNA from biological samples

Inventors: Hamid Khoja (Rancho Santa Margarita, CA); Hans-Ulrich Thomann (Stow, MA); James A. Laugharn, Jr. (Boston, MA)
Assignee: Covaris, Inc.
C12N15/1003C12N13/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,781,439
App. No.
15/473,672
Granted
Sep 22, 2020
Kind
B2
Abstract

Focused acoustic treatment of samples including a target biomolecule, such as cfDNA, may aid in the recovery of the biomolecule from a sample. cfDNA in a sample, whether chemically stabilized or not, may be linked or otherwise bound to histones or other proteins, e.g., by hydrogen bonds of histones or chaperone proteins to DNA and/or covalent crosslinks of such proteins to the DNA. Focused acoustic energy may remove or disrupt such links, aiding in isolation of the cfDNA from the sample.

Claims (23)

1. A method for processing a sample containing a biomolecule to be recovered from the sample, comprising:

providing an initial sample including cfDNA and whole cells;

separating cfDNA from the whole cells in the initial sample to provide a sample containing cfDNA;

providing the sample containing cfDNA that has histones and/or other proteins bound to the cfDNA in an acoustic treatment vessel;

exposing the sample in the vessel to focused acoustic energy specifically adapted to remove or disrupt bonds between the cfDNA and bound histones and/or other proteins such that the specifically adapted focused acoustic energy alone acts to remove or disrupt bonds between the cfDNA and bound histones and/or other proteins without shearing of the cfDNA; and

extracting the cfDNA from the sample after bonds between the cfDNA and bound histones and/or other proteins have been removed or disrupted by the focused acoustic energy;

wherein the focused acoustic energy has a duty cycle of at least 5%, a 10 W to 80 W Peak Incident Power (PIP), and 50 cycles per burst for a processing time of 5 seconds to 120 seconds per sample.

2. The method of claim 1 , wherein the sample containing cfDNA is previously chemically stabilized prior to being provided in the acoustic treatment vessel.

3. The method of claim 1 , wherein the sample is a portion of a blood sample.

4. The method of claim 3 , wherein the blood sample is chemically stabilized with a fixative.

5. The method of claim 3 , wherein the sample includes serum separated from the blood sample by centrifugation.

6. The method of claim 1 , wherein the acoustic treatment vessel is positioned in a fluid coupling medium that transmits the focused acoustic energy to the vessel.

7. The method of claim 1 , wherein the step of exposing the sample in the vessel to focused acoustic energy includes moving a focal zone of the acoustic energy relative to the sample, and wherein a volume of the focal zone is less than a volume of the sample.

8. The method of claim 1 , wherein the step of exposing the sample in the vessel to focused acoustic energy includes maintaining a focal zone of the acoustic energy stationary relative to the sample, and wherein a volume of the focal zone is larger than a volume of the sample.

9. The method of claim 1 , wherein the sample is not chemically stabilized.

10. The method of claim 1 , wherein the step of exposing enhances a reverse crosslinking rate of histones to the cfDNA.

11. The method of claim 1 , wherein the step of exposing disrupts hydrogen bonding of histones or chaperone proteins to the cfDNA.

12. The method of claim 1 , wherein bonds between cfDNA and bound histones and/or other proteins were created by chemical stabilization.

13. The method of claim 1 , wherein the sample includes blood, spinal fluid, saliva, sputum, stool or urine.

14. The method of claim 1 , wherein the sample is treated with a stabilization compound including a formaldehyde-providing compound or a disaccharide prior to being provided in the acoustic treatment vessel.

15. The method of claim 1 , wherein the focused acoustic energy is generated by an acoustic energy source spaced from and exterior to the vessel, and the focused acoustic energy comprises a frequency of between about 100 kilohertz and about 100 megahertz and a focal zone having a width of less than about 2 centimeters.

16. The method of claim 15 , wherein the acoustic energy source includes an acoustic transducer having a dome shape and arranged to generate focused acoustic energy to create the focal zone.

17. The method of claim 1 , wherein the sample has a volume of 10 microliters to 150 milliliters.

Assignments (5)
SECURITY INTEREST Recorded Feb 7, 2024
From: COVARIS, LLC
To: BLUE OWL CAPITAL CORPORATION
Reel/Frame 066511/0843 →
RELEASE OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (058887/0048) Recorded Dec 4, 2023
From: ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
To: COVARIS, LLC
Reel/Frame 065759/0122 →
SECURITY INTEREST Recorded Jan 27, 2022
From: COVARIS, LLC
To: ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 058887/0048 →
CHANGE OF NAME Recorded Jan 19, 2022
From: COVARIS, INC.
To: COVARIS, LLC
Reel/Frame 058768/0261 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2017
From: KHOJA, HAMID; THOMANN, HANS-ULRICH; LAUGHARN, JAMES A., JR
To: COVARIS, INC.
Reel/Frame 042251/0579 →
Continuity (2)
Provisional Application 62315341 · Mar 30, 2016
Related Publication 20170283788A1 · Oct 5, 2017